Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
| Authors | |
|---|---|
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | International Journal of Molecular Sciences |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.mdpi.com/1422-0067/22/11/5536 |
| Doi | http://dx.doi.org/10.3390/ijms22115536 |
| Keywords | chimeric antigen receptor; immunotherapy; chronic lymphocytic leukemia; CD19 |
| Description | Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease. |
| Related projects: |